{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:03:56Z","timestamp":1767175436964,"version":"build-2238731810"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older individuals with multiple comorbidities and especially patients with multiple myeloma are at higher risk of contracting SARS-CoV-2. When patients with multiple myeloma (MM) are also affected by SARS-CoV-2 the time to start immunosuppressants is still a clinical dilemma especially when urgent hemodialysis is required for acute kidney injury (AKI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a case of an 80-year-old woman who was diagnosed with AKI in MM. The patient began hemodiafiltration (HDF) with free light chain removal combined with bortezomib and dexamethasone. The reduction of free light chains concurrently was obtained by means of HDF using poly ester polymer alloy (PEPA) high-flux filter: 2 PEPA filters were used in series during each 4-h length HDF session. A total of 11 sessions was carried out. The hospitalization was complicated with acute respiratory failure caused by SARS-CoV-2 pneumonia successfully treated with both pharmacotherapy and respiratory support. Once the respiratory status stabilized MM treatment was resumed.<\/jats:p>\n                    <jats:p>The patient was discharged in stable condition after 3\u00a0months of hospitalization. The follow up showed significant improvement of the residual renal function which allowed interruption of hemodialysis (HD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The complexity of patients affected by MM, AKI, and SARS-CoV-2 should not discourage the attending physicians to offer the adequate treatment. The cooperation of different specialists can lead to a positive outcome in those complicated cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03237-8","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T03:02:35Z","timestamp":1688612555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute myeloma kidney and SARS-COV2 infection with dialysis need: never say never - a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Gabriele","family":"Donati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Przygocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Zappulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisella","family":"Vischini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-8551","authenticated-orcid":false,"given":"Gaetano","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"issue":"2","key":"3237_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfq421","volume":"26","author":"G Cianciolo","year":"2011","unstructured":"Cianciolo G, La Manna G, Donati G, Dormi A, Cappuccilli ML, Cuna V, et al. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. Nephrol Dial Transplant. 2011;26(2):646\u201352.","journal-title":"Nephrol Dial Transplant"},{"issue":"8533","key":"3237_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(87)90266-2","volume":"1","author":"J Bergstr\u00f6m","year":"1987","unstructured":"Bergstr\u00f6m J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987;1(8533):628\u20139.","journal-title":"Lancet"},{"issue":"36","key":"3237_CR3","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2015","unstructured":"Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered on to the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2015;23(36):9219\u201326.","journal-title":"J Clin Oncol"},{"key":"3237_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195\u2013200.","journal-title":"Ann Oncol"},{"key":"3237_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/leu.2015.15","volume":"29","author":"R Khan","year":"2015","unstructured":"Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia. 2015;29:1195\u2013201.","journal-title":"Leukemia"},{"key":"3237_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313.","journal-title":"Haematologica"},{"issue":"1","key":"3237_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","volume":"26","author":"M Syed-Ahmed","year":"2019","unstructured":"Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2019;26(1):8\u201315.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"3237_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/toxins12070439","volume":"12","author":"G Cohen","year":"2020","unstructured":"Cohen G. Immune Dysfunction in Uremia 2020. Toxins (Basel). 2020;12(7):439.","journal-title":"Toxins (Basel)."},{"issue":"4","key":"3237_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004100","volume":"4","author":"HI McDonald","year":"2014","unstructured":"McDonald HI, Thomas SL, Nitsch D. Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open. 2014;4(4): e004100.","journal-title":"BMJ Open"},{"issue":"12","key":"3237_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1086\/424516","volume":"39","author":"S Berman","year":"2004","unstructured":"Berman S, Johnson E, Nakatsu C, Alkan M, Chen R, LeDuc J. Burden of Infection in Patients with End-Stage Renal Disease Requiring Long-Term Dialysis. Clin Infect Dis. 2004;39(12):1747\u201353.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3237_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ejh.13190","volume":"102","author":"R S\u00f8rrig","year":"2019","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102(2):182\u201390.","journal-title":"Eur J Haematol"},{"key":"3237_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","volume":"31","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894\u2013901.","journal-title":"Ann Oncol"},{"key":"3237_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335\u20137.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3237_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783\u201391.","journal-title":"Cancer Discov"},{"key":"3237_CR15","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-L\u00f3pez J, Mateos MV, Encinas C, Sureda A, Hern\u00e1ndez-Rivas J\u00c1, Lopez de la Gu\u00eda A,\u00a0et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of in-patient mortality.\u00a0Blood Cancer J.\u00a02020;10:103.","DOI":"10.1038\/s41408-020-00372-5"},{"key":"3237_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.16874","volume":"190","author":"G Cook","year":"2020","unstructured":"Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:83\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"3237_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ajh.26762","volume":"98","author":"M Ho","year":"2023","unstructured":"Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023;98(1):49\u201355.","journal-title":"Am J Hematol"},{"issue":"10","key":"3237_CR18","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00277-021-04594-w","volume":"100","author":"M Krejci","year":"2021","unstructured":"Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Ann Hematol. 2021;100(10):2541\u20136.","journal-title":"Ann Hematol"},{"issue":"6","key":"3237_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12185-021-03175-x","volume":"114","author":"M Hagihara","year":"2021","unstructured":"Hagihara M, Ohara S, Uchida T, Inoue M. Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan. Int J Hematol. 2021;114(6):709\u201318.","journal-title":"Int J Hematol"},{"issue":"13","key":"3237_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34(13):1544\u201357.","journal-title":"J Clin Oncol"},{"key":"3237_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/sj.leu.2405087","volume":"22","author":"JF San-Miguel","year":"2008","unstructured":"San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia. 2008;22:842\u20139.","journal-title":"Leukemia"},{"key":"3237_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","volume":"9","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9:302\u20136.","journal-title":"Clin Lymphoma Myeloma"},{"key":"3237_CR23","doi-asserted-by":"crossref","unstructured":"Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 2010;84(3):223\u20138.","DOI":"10.1111\/j.1600-0609.2009.01385.x"},{"issue":"5","key":"3237_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.24335","volume":"91","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499\u2013502.","journal-title":"Am J Hematol"},{"issue":"8","key":"3237_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","volume":"34","author":"E Terpos","year":"2020","unstructured":"Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000\u201311.","journal-title":"Leukemia"},{"issue":"8","key":"3237_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"10","key":"3237_CR27","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1093\/ndt\/gfr773","volume":"27","author":"CA Hutchison","year":"2012","unstructured":"Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27(10):3823\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"3237_CR28","doi-asserted-by":"crossref","unstructured":"Bridoux F, Carron P-L, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A,\u00a0et al. MYRE Study Group. Effect of high cut-off hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA. 2017;318(21):2099\u20132110.","DOI":"10.1001\/jama.2017.17924"},{"issue":"4","key":"3237_CR29","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","volume":"6","author":"CA Hutchison","year":"2019","unstructured":"Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, et al. High cut-off versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):e217\u201328.","journal-title":"Lancet Haematol"},{"issue":"11","key":"3237_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","volume":"73","author":"N Leung","year":"2008","unstructured":"Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282\u20138.","journal-title":"Kidney Int"},{"key":"3237_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1542-4758.2010.00481.x","volume":"14","author":"D Gupta","year":"2010","unstructured":"Gupta D, Bachegowda L, Phadke G, Boren S, Johnson D, Misra M. Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int. 2010;14:355\u201363.","journal-title":"Hemodial Int"},{"key":"3237_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1525-1594.2008.00653.x","volume":"32","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32:910\u20137.","journal-title":"Artif Organs"},{"key":"3237_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/ndt\/gfp488","volume":"25","author":"RJ Haynes","year":"2010","unstructured":"Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25:419\u201326.","journal-title":"Nephrol Dial Transplant"},{"key":"3237_CR34","doi-asserted-by":"crossref","unstructured":"Hutchison CA, Cockwell P, Reid S, et. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18(3):886\u2013895.","DOI":"10.1681\/ASN.2006080821"},{"key":"3237_CR35","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/ndt\/17.9.1689","volume":"17","author":"T Machiguchi","year":"2002","unstructured":"Machiguchi T, Tamura T, Yoshida H. Efficacy of haemodiafiltration treatment with PEPA dialysis membranes in plasma free light chain removal in a patient with primary amyloidosis. Nephrol Dial Transplant. 2002;17:1689\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"3237_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000350849","volume":"35","author":"P Fabbrini","year":"2013","unstructured":"Fabbrini P, Sirtori S, Casiraghi E, et al. Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties. Blood Purif. 2013;35(Suppl 2):52\u20138.","journal-title":"Blood Purif"},{"key":"3237_CR37","doi-asserted-by":"publisher","first-page":"E97","DOI":"10.1111\/hdi.12733","volume":"23","author":"G Donati","year":"2019","unstructured":"Donati G, Zappulo F, Croci Chiocchini AL, Comai G, Zamagni E, La Manna G. Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report. Hemodialysis Int. 2019;23:E97\u20139.","journal-title":"Hemodialysis Int"},{"issue":"6","key":"3237_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/toxins14060391","volume":"14","author":"G Donati","year":"2022","unstructured":"Donati G, Zappulo F, Maietti E, Scrivo A, Gasperoni L, Zamagni E, et al. Early light chains removal and albumin levels with a double filter-based extracorporeal treatment for acute myeloma kidney. Toxins (Basel). 2022;14(6):391.","journal-title":"Toxins (Basel)"}],"updated-by":[{"DOI":"10.1186\/s12882-023-03301-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000}}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03237-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T09:20:24Z","timestamp":1700472024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03237-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3237"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03237-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12882-023-03301-3","URL":"https:\/\/doi.org\/10.1186\/s12882-023-03301-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish images were obtained from the subject.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}